Toward fulfilling the promise of molecular medicine in fragile X syndrome

Annual Review of Medicine

Volumn 62, Issue , 2011, Pages 411-429

  Krueger, Dilja D ^a   Bear, Mark F ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

autism; FMRP; long term depression; mental retardation; metabotropic glutamate receptor; protein synthesis

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ACAMPROSATE; AFQ 056; ANTISENSE OLIGONUCLEOTIDE; ARBACLOFEN PLACARBIL; BACLOFEN; FENOBAM; FRAGILE X MENTAL RETARDATION PROTEIN; LITHIUM; MESSENGER RNA; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; METHYL CPG BINDING PROTEIN 2; MEVINOLIN; MINOCYCLINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; RECEPTOR BLOCKING AGENT; RO 4917523; SOMATOMEDIN C; STX 107; STX 209; UNCLASSIFIED DRUG;

ARTICLE; AUTISM; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TARGETING; FRAGILE X SYNDROME; GENE MUTATION; HUMAN; IDIOPATHIC DISEASE; KNOCKOUT MOUSE; LONG TERM DEPRESSION; NERVE CELL PLASTICITY; NEUROFIBROMATOSIS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECEPTOR BLOCKING; RETT SYNDROME; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUBEROUS SCLEROSIS;

ANIMALS; AUTISTIC DISORDER; CLINICAL TRIALS AS TOPIC; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MICE; NEUROFIBROMATOSIS 1; NEURONAL PLASTICITY; PTEN PHOSPHOHYDROLASE; RECEPTORS, METABOTROPIC GLUTAMATE; RETT SYNDROME; TUBEROUS SCLEROSIS;

EID: 79551594543     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-061109-134644     Document Type: Article

References (102)

1. Hyman SE. 1988. The role of molecular biology in psychiatry. Psychosomatics 29:328-32
2. Abrahams BS, Geschwind DH. 2008. Advances in autism genetics: on the threshold of a new neurobi-ology. Nat. Rev. Genet. 9:341-55
3. Kogan MD, Blumberg SJ, Schieve LA, et al. 2009. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 124:1395-403
4. Martin JP, Bell J. 1943. A pedigree of mental defect showing sex-linkage. J. Neurol. Psychiatry 6:154-57
5. Penagarikano O, Mulle JG, Warren ST. 2007. The pathophysiology of fragile X syndrome. Annu. Rev. Genomics Hum. Genet. 8:109-29
6. Lubs H. 1969. A marker X chromosome. Am. J. Hum. Genet. 21:231-44
7. Sutherland GR. 1977. Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science 197:265-66
8. Verkerk AJMH, Pieretti M, Sutcliffe JS, et al. 1991. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-14
9. Ashley C, Wilkinson K, Reines D, et al. 1993. FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262:563-66
10. Dutch Belgian Fragile X Consortium, Bakker CE, Verheij C, Willemsen R, et al. 1994. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78:23-33
11. Corbin F, Bouillon M, Fortin A. 1997. The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes. Hum. Mol. Genet. 6:1465-72
12. Khandjian EW, Corbin F, Woerly S, et al. 1996. The fragile X mental retardation protein is associated with ribosomes. Nat. Genet. 12:91-93
13. Tamanini F, Meijer N, Verheij C, et al. 1996. FMRP is associated to the ribosomes via RNA. Hum. Mol. Genet. 5:809-13
14. O'Donnell WT, Warren ST. 2002. A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 25:315-38
15. Laggerbauer B, Ostareck D, Keidel EM, et al. 2001. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum. Mol. Genet. 10:329-38
16. Li Z, Zhang Y, Ku L, et al. 2001. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 29:2276-83
17. Huber KM, Gallagher SM, Warren ST, et al. 2002. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 99:7746-50
18. Bassell GJ, Warren ST. 2008. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60:201-14
19. Pfeiffer BE, Huber KM. 2009. The state of synapses in fragile X syndrome. Neuroscientist 15:549-67
20. Bramham CR, Wells DG. 2007. Dendritic mRNA: transport, translation and function. Nat. Rev. Neurosci. 8:776-89
21. Comery TA, Harris JB, Willems PJ, et al. 1997. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc. Natl. Acad. Sci. USA 94:5401-4
22. Hinton VJ, Brown WT, Wisniewski K, et al. 1991. Analysis of neocortex in three males with the fragile X syndrome. Am. J. Med. Genet. 41:289-94
23. Irwin SA, Galvez R, Greenough WT. 2000. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb. Cortex 10:1038-44
24. Pfeiffer BE, Huber KM. 2007. Fragile X mental retardation protein induces synapse loss through acute postsynaptic translational regulation. J. Neurosci. 27:3120-30
25. Koekkoek SKE, Yamaguchi K, Milojkovic BA, et al. 2005. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron 47:339-52
26. Li J, Pelletier MR, Perez Velazquez JL, et al. 2002. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol. Cell. Neurosci. 19:138-51
27. Desai NS, Casimiro TM, Gruber SM, et al. 2006. Early postnatal plasticity in neocortex ofFmr1 knockout mice. J. Neurophysiol. 96:1734-45
28. Wilson BM, Cox CL. 2007. Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc. Natl. Acad. Sci. USA 104:2454-59
29. Zhao MG, Toyoda H, Ko SW, et al. 2005. Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J. Neurosci. 25:7385-92
30. Auerbach BD, Bear MF. 2010. Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. J. Neurophysiol. 104:1047-51
31. Nicoletti FMJ, Iadarola MJ, Chuang DM, et al. 1986. Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus. J. Neurochem. 46:40-46
32. Hirono C, Ito I, Yamagishi S, et al. 1988. Characterization of glutamate receptors induced in Xenopus oocytes after injection of rat brain mRNA. Neurosci. Res. 6:106-14
33. Houamed KM, Kuijper JL, Gilbert TL, et al. 1991. Cloning, expression, and gene structure of a G protein-coupled glutamate receptor from rat brain. Science 252:1318-21
34. Conn PJ. 2003. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann. NY Acad. Sci. 1003:12-21
35. Weiler IJ, Greenough WT. 1993. Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc. Natl. Acad. Sci. USA 90:7168-71
36. Wiesel T, Hubel D. 1963. Single-cell responses in striate cortex of kittens deprived of vision in one eye. J. Neurophysiol. 26:1003-17
37. Bienenstock E, Cooper L, Munro P. 1982. Theory for the development of neuron selectivity: orientation specificity and binocular interaction in visual cortex. J. Neurosci. 2:32-48
38. Bear MF. 1988. Involvement of excitatory amino acid receptor mechanisms in the experience-dependent development of visual cortex. In Recent Advances in Excitatory Amino Acid Research, ed. J Lehman, L Turski, pp. 393-401. New York: Liss
39. Dudek S, Bear MF. 1992. Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade. Proc. Natl. Acad. Sci. USA 89:4363-67
40. Huber KM, Roder JC, Bear MF. 2001. Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1. J. Neurophysiol. 86:321-25
41. Oliet SHR, Malenka RC, Nicoll RA. 1997. Two distinct forms of long-term depression coexist in CA1 hippocampal pyramidal cells. Neuron 18:969-82
42. Palmer MJ, Irving AJ, Seabrook GR, et al. 1997. The group I mGlu receptor agonist DHPG induces a novel form of LTD in the CA1 region of the hippocampus. Neuropharmacology 36:1517-32
43. Snyder EM, Philpot BD, Huber KM, et al. 2001. Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat. Neurosci. 4:1079-85
44. Huber KM, Kayser MS, Bear MF. 2000. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 288:1254-56
45. Gladding CM, Fitzjohn SM, Molnar E. 2009. Metabotropic glutamate receptor-mediated long-term depression: molecular mechanisms. Pharmacol. Rev. 61:395-412
46. Weiler IJ, Irwin SA, Klintsova AY, et al. 1997. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc. Natl. Acad. Sci. USA 94:5395-400
47. Qin M, Kang J, Burlin TV, et al. 2005. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the Fmr1 null mouse. J. Neurosci. 25:5087-95
48. Dolen G, Osterweil E, Rao BSS, et al. 2007. Correction of fragile X syndrome in mice. Neuron 56:955-62
49. Merlin LR, Bergold PJ, Wong RK. 1998. Requirement of protein synthesis for group I mGluR-mediated induction of epileptiform discharges. J. Neurophysiol. 80:989-93
50. Vanderklish PW, Edelman GM. 2002. Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA 99:1639-44
51. Raymond CR, Thompson VL, Tate WP, et al. 2000. Metabotropic glutamate receptors trigger homosy-naptic protein synthesis to prolong long-term potentiation. J. Neurosci. 20:969-76
52. Bear MF, Huber KM, Warren ST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27:370-77
53. Chuang SC, Zhao W, Bauchwitz R, et al. 2005. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J. Neurosci. 25:8048-55
54. Nakamoto M, Nalavadi V, Epstein MP, et al. 2007. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc. Natl. Acad. Sci. USA 104:15537-42
55. Nosyreva ED, Huber KM. 2006. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J. Neurophysiol. 95:3291-95
56. Hou L, Antion MD, Hu D, et al. 2006. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51:441-54
57. Giuffrida R, Musumeci S, D'Antoni S, et al. 2005. A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive Homer proteins in a mouse model of fragile X syndrome. J. Neurosci. 25:8908-16
58. Ronesi JA, Huber KM. 2008. Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J. Neurosci. 28:543-47
59. Kim SH, Markham JA, Weiler IJ, et al. 2008. Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc. Natl. Acad. Sci. USA 105:4429-34
60. Sharma A, Hoeffer CA, Takayasu Y, et al. 2010. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 30:694-702
61. Gross C, Nakamoto M, Yao X, et al. 2010. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J. Neurosci. 30:10624-38
62. Osterweil EK, Krueger DD, Reinhold K, et al. 2010. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 30:15616-27
63. Waung MW, Huber KM. 2009. Protein translation in synaptic plasticity: mGluR-LTD, fragile X. Curr. Opin. Neurobiol. 19:319-26
64. Pan L, Broadie KS. 2007. Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A convergently regulate the synaptic ratio of ionotropic glutamate receptor subclasses. J. Neurosci. 27:12378-89
65. Pan L, Woodruff E III, Liang P, et al. 2008. Mechanistic relationships between Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A signaling. Mol. Cell. Neurosci. 37:747-60
66. Repicky S, Broadie K. 2009. Metabotropic glutamate receptor-mediated use-dependent down-regulation of synaptic excitability involves the fragile X mental retardation protein. J. Neurophysiol. 101:672-87
67. Gasparini F, Lingenhöhl K, Stoehr N, et al. 1999. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-503
68. Yan QJ, Rammal M, Tranfaglia M, et al. 2005. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49:1053-66
69. de Vrij FMS, Levenga J, van der Linde HC, et al. 2008. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol. Dis. 31:127-32
70. Aschrafi A, Cunningham BA, Edelman GM, et al. 2005. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc. Natl. Acad. Sci. USA 102:2180-85
71. Min WW, Yuskaitis CJ, Yan Q, et al. 2009. Elevated glycogen synthase kinase-3 activity in fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 56:463-72
72. McBride SMJ, Choi CH, Wang Y, et al. 2005. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45:753-64
73. Bolduc FV, Bell K, Cox H, et al. 2008. Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nat. Neurosci. 11:1143-45
74. Chang S, Bray SM, Li Z, et al. 2008. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4:256-63
75. Tucker B, Richards RI, Lardelli M. 2006. Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum. Mol. Genet. 15:3446-58
76. Zalfa F, Eleuteri B, Dickson KS, et al. 2007. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat. Neurosci. 10:578-87
77. Suvrathan A, Hoeffer CA, Wong H, et al. 2010. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. 107:11591-96
78. Cruz-Martin A, Crespo M, Portera-Cailliau C. 2010. Delayed stabilization of dendritic spines in fragile X mice. J. Neurosci. 30:7793-803
79. Lea PM, Faden AI. 2006. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev. 12:149-66
80. Berry-Kravis E. 2008. Fragile X research: a status report. Natl. Fragile X Found. Q. 31:12-16
81. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. 2009. Advances in the treatment of fragile X syndrome. Pediatrics 123:378-90
82. Porter RHP, Jaeschke G, Spooren W, et al. 2005. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315:711-21
83. Berry-Kravis EM, Hessl D, Coffey S, et al. 2009. A pilot open-label single-dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 46:266-71
84. Erickson CA, Mullett JE, McDougle CJ. 2010. Brief report: acamprosate in fragile X syndrome. J. Autism Dev. Disord. Epub ahead of print
85. Berry-Kravis E, Sumis A, Hervey C, et al. 2008. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J. Dev. Behav. Pediatr. 29:293-302
86. Pacey LKK, Heximer SP, Hampson DR. 2009. Increased GABAB receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol. Pharmacol. 76:18-24
87. Bilousova TV, Dansie L, Ngo M, et al. 2009. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 46:94-102
88. Silva AJ, Ehninger D. 2009. Adult reversal of cognitive phenotypes in neurodevelopmental disorders. J. Neurodev. Disord. 1:150-57
89. Ehninger D, de Vries PJ, Silva AJ. 2009. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J. Intellect. Disabil. Res. 53:838-51
90. Ehninger D, Han S, Shilyansky C, et al. 2008. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 14:843-48
91. Zhou J, Blundell J, Ogawa S, et al. 2009. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J. Neurosci. 29:1773-83
92. Li W, Cui Y, Kushner SA, et al. 2005. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 15:1961-67
93. Krab LC, de Goede-Bolder A, Aarsen FK, et al. 2008. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 300:287-94
94. Guy J, Gan J, Selfridge J, et al. 2007. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315:1143-47
95. Tropea D, Giacometti E, Wilson NR, et al. 2009. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. USA 106:2029-34
96. Kelleher RJ, Bear MF. 2008. The autistic neuron: troubled translation? Cell 135:401-6
97. Neves-Pereira M, Müller B, Massie D, et al. 2009. Deregulation of EIF4E: a novel mechanism for autism. J. Med. Genet. 46:759-65
98. Pinto D, Pagnamenta AT, Klei L, et al. 2010. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466:368-72
99. Sudhof TC. 2008. Neuroligins and neurexins link synaptic function to cognitive disease. 455:903-11
100. Toro R, Konyukh M, Delorme R, et al. 2010. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet. 26:363-72
101. Betancur C, Sakurai T, Buxbaum JD. 2009. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci. 32:402-12
102. Blundell J, Blaiss CA, Etherton MR, et al. 2010. Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J. Neurosci. 30:2115-29